JPRN-jRCT2080222062未知2 期
Exploratory Phase II Study of KRP-203 -A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of KRP-203 in Patients with Crohn's Disease in Active Phase
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Patients who were diagnosed with Crohn's disease according to diagnostic criteria, etc.
排除标准
- •-Patients with a colostomy or ileostomy.
- •-Patients with a short gut syndrome or imflammatory bowel disease except Crohn's disease, etc.
研究者
相似试验
未知
2 期
Phase II Study of KRP-209Subjective tinnitusJPRN-jRCT2080221608Kyorin Pharmaceutical Co.,LTD400
未知
2 期
K-104-CR Phase II Exploratory studyHypercholesterolemiaJPRN-jRCT2080222137Kowa Co., Ltd.24
未知
2 期
KRP-104Phase 2 Dose Finding Study -Investigation on Type2 Diabetes MellitusJPRN-jRCT2080220708Kyorin Pharmaceutical Co.,LTD
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of dapagliflozin and dapagliflozinin combination with saxagliptin in type 2 diabetes with kidney disease.CKD3 patients with type 2 diabetes mellitus and albuminuria.MedDRA version: 18.0Level: LLTClassification code 10045250Term: Type II diabetes mellitus with renal manifestationsSystem Organ Class: 100000004857EUCTR2015-002676-24-ESAstraZeneca AB1,125
进行中（未招募）
1 期
A Randomized Controlled Phase 2 Trial of ARQ 197 inPatients with Unresectable Hepatocellular Carcinoma(HCC) Who Have Failed One Prior Systemic Therapynresectable hepatocellular carcinoma (HCC)MedDRA version: 14.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007155-27-BEArQule, Inc.99